Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Published Online: 2018-07-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Abby B Siegel•Alan Weiss•Allen Cohn•Andrea L Webber•Andreas Kaubisch•Andrew S. Paulson•Andrew X Zhu•Angela Alistar•Ann-Lii Cheng•Arndt Vogel•Atisha Manhas•Benjamin Parsons•Bruno Daniele•Carmine Pinto•Chris Verslype•Daneng Li•Daniel Palmer•David P Cosgrove•Debashis Sarker•Gina Vaccaro•Gontran Verset•Gulam Abbas Manji•Hans Van Vlierberghe•Ivan Borbath•James Lee•Jamil Asselah•Jean-Frederic Blanc•Jena-Luc Van Laethem•Jennifer Knox•Joerg Trojan•Julien Edeline•Junshui Ma•Karl-Heinz Weiss•Kazushi Numata•Ki Chung•Laetitia Fartoux•Magnus Rizell•Mark Karwal•Masatoshi Kudo•Mukul Gupta•Nevena Damjanov•Olivier Rosmorduc•Per I Stal•Richard S Finn•Robert Ramirez•Robin Kelley•Sadahisa Ogasawara•Scot W Ebbinghaus•Simone Strasser•Stephane Cattan•Stephen L Chan•Suresh Ratnam•Tatsuya Yamashita•Timothy Cannon•Timothy Larson•Vittorina Zagonel•Yoshivasu Karino•Yutaka Sasaki•Yvonne Sada
